Pérez FGA, Isidor SG, Martín RL, Suárez HR, Rodríguez GE, Sarda RJ

Language: Spanish
References: 20
Page: 129-137
PDF size: 352.07 Kb.

ABSTRACT

Introduction: In March 2020, COVID-19 is declared a pandemic. The transmissibility of SARS-CoV-2 in asymptomatic patients, who could infect others, greatly complicates the detection of new cases.
Objectives: We sought to identify the degree of association of epidemiological factors and comorbidities associated with asymptomatic and symptomatic states, as well as ascertain the main manifestations in these individuals and determine the behavior of laboratory test results.
Methods: A cross-sectional descriptive study was conducted on a sample of 52 patients with underlying cardiovascular disease, diagnosed with COVID-19 and admitted to the Hospital Universitario Celestino Hernández Robau in Santa Clara (Cuba), a facility exclusively devoted to the care of such patients during the pandemic.
Results: High blood pressure predominated among the associated comorbidities (32.7%) and dry cough was the most frequent symptom (75%), followed by fever (25%). None of the subjects developed severe symptoms of COVID-19, nor did they die. The highest proportion of cases corresponded to asymptomatic patients (61.5%). Hypercholesterolemia was close to but not yet significant (OR=0.97; CI 0.82-1.16; p=0.06). Mean erythrocyte sedimentation values were higher in asymptomatic than symptomatic patients (CI 8.45-33.74; p=0.02).
Conclusions: In individuals with heart disease the relationship between epidemiological factors and associated comorbidities was similar in asymptomatic and symptomatic states. Results of most laboratory tests yielded no differences between the two types of patients.

REFERENCES

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-207.

2. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568-76.

3. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-23.

4. World Health Organization. Coronavirus (COVID-19) - WHO Health Emergency Dashboard [Internet]. 2020 [citado 12/05/2020]. Disponible en: https://covid19. who. int/

5. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-9.

6. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.

7. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.

8. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

9. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-6.

10. Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis (Lond). 2020;52(7):498-505.

11. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China. JAMA Netw Open [Internet]. 2020 [citado 13/05/2020];3(4):e205619. Disponible en: http://doi. org/10. 1001/jamanetworkopen. 2020. 5619

12. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046-53.

13. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020;134(5):543-5.

14. Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities. J Racial Ethn Health Disparities. 2020;7(3):398-402.

15. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049-57.

16. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty [Internet]. 2020 [citado 14/05/2020];9(1):29. Disponible en: https://idpjournal. biomedcentral. com/track/pdf/10. 1186/s40249-020-00646-x

17. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9.

18. World Health Organization. Novel Coronavirus (2019-nCoV). Situation Report-11 [Internet]. 2020 [citado 15/05/2020]. Disponible en: https://www. who. int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov. pdf?sfvrsn=de7c0f7_4

19. Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clin Infect Dis [Internet]. 2020 [citado 16/05/2020]:ciaa538. Disponible en: http://doi. org/10. 1093/cid/ciaa538

20. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis (Berl). 2020;7(2):91-6.